Company Logo
Current Event and Historical Highlights.  Scientific image.

February 2, 2017

Today, Crystal’s patent portfolio was strengthened by the Australian patent office grant of 2012258786 entitled “Transgenic chicken comprising an inactivated immunoglobulin gene" to Crystal Bioscience.

January 24, 2017

The USPTO granted 9,549,538 entitled Transgenic animal for production of antibodies having minimal CDRs to Crystal Bioscience. This patent is the third in this series of patents protecting Crystal’s HuMab chickens.

December 21 2016

Crystal Bioscience expand its collaboration with the Boehringer Ingelheim to develop panels of monoclonal from Crystal’s HuMab antibody discovery platform. See

December 12, 2016

The Crystal Bioscience platform was presented in two posters at the Antibody Engineering & Therapeutics Conference entitled “Generation of Transgenic Chickens Producing Antibodies with Fully-Human Variable Regions” and “Human antibodies from Transgenic Chickens”.

December 6, 2016

Dr. Bill Harriman was an invited speaker at the Protein Discovery Summit in Boston. His talk was entitled “HuMab Chickens: human antibodies from transgenic chickens.”

October 10, 2016

Dr Rob Etches was the guest speaker at the 11th International Symposium on Avian Endocrinology. In his address entitled “Designer chickens –from concept to reality” he described the technology developed at Crystal Bioscience to create Crystal’s HuMab antibody discovery platform and extrapolated on application of these tools to create new opportunities in the field of avian biology.

October 6, 2016

Crystal Bioscience Forms Collaboration With the Scripps Research Institute and the Georgia Institute of Technology to Develop Panels of Monoclonal Antibodies to Glycan Antigens. See

September 22, 2016

Discovery on Target, Boston, MA. Dr. Bill Harriman gave a talk entitled “HuMab Chickens: a new path for therapeutic antibody discovery,” describing the functionality of Crystal’s proprietary genetically engineered chickens that produce human sequence antibodies. Also at DOT, Dr. Kathryn Ching, presented data detailing the properties of fully human recombinant antibodies derived from HuMab Chickens, and Dr. Marie-Cecile van de Lavoir presented a poster describing the strategies and genetic engineering methodologies underlying the creation of the HuMab Chicken.

September 7, 2016

Crystal Bioscience appoints Herb Heyneker to its Board of Directors. See

August 19, 2016

Marie-Cecile van de Lavoir, COO, presented at the North America Ornithology Conference on the use of primordial germ cells as a route to access the avian genome. She presented data on the culture of primordial germ cells from several avian species and described how primordial germ cells can be used in species conservation.

July 21, 2016

Crystal Bioscience was awarded a Phase I SBIR grant entitled “Novel Avian CCR5 Specific Antibodies to block HIV transmission”. These funds will be used to augment the panel of CCR5 specific antibodies raised at Crystal during a proof-of-principle trial. “Our unique approach to developing an HIV therapy is Crystal’s first entry into infectious diseases” said Bill Harriman, CSO at Crystal and the Principal Investigator on the grant. “Prior therapeutic assets have been created for applications in oncology, pain, neurology and autoimmune diseases”.

July 19, 2016

The United States Patent and Trademark Office issued Patent # 9,394,372 entitled “In vivo method for generating diversity in a protein scaffold” to Crystal Bioscience. Issued claims include a transgenic chicken producing heavy-chain-only antibodies.

July 9, 2016

Crystal Bioscience published “Expression of heavy-chain-only antibodies can support B cell development in light chain knock-out chickens” in the European Journal of Immunology. This knock-out complements previous knock outs at the immunoglobulin heavy chain locus [links to PNAS, and PlosOne(Dimitrov) papers], demonstrates that chickens can make heavy-chain-only antibodies and shows that the chicken has only one functional light chain. The excised light chain gene in these birds is now replaced with its human counterpart in Crystal’s Hu-Mab chicken. [Press Release]

July 5, 2016

The United States Patent and Trademark Office issued Patent # 9,380,769 entitled “Transgenic chicken comprising an inactivated immunoglobulin gene” to Crystal Bioscience.

June 3, 2016

Dr. Rob Etches, President & CEO at Crystal Bioscience was the keynote speaker at the 30th Annual Symposium of the Department of Animal and Avian Sciences at the University of Maryland. Dr. Etches described Crystal’s HuMab chicken and the company’s genetic engineering technology that was used to create it.

May 10, 2016

Achaogen and Crystal Bioscience announce their collaboration and license agreement to develop antibodies against multiple targets. [News Release]

April 25-26, 2016

Rob Etches, CEO at Crystal Bioscience presented a poster entitled “Human antibodies from transgenic chickens” at the PEGS summit in Boston. A second poster entitled “Antibodies against difficult-to-express membrane protein targets” co-authored by Ellen Collarini, Director of Cell Biology at Crystal Bioscience and Yelena Bisharyan, Director of External Alliances at Tetragenetics was presented in the same session. Dr, Bisharyan was selected by the PEGS review committee to highlight these data as an oral presentation.

April 21, 2016

High-efficiency interrogation of single B cells is a hallmark of Crystal Bioscience’s antibody discovery platforms. The details of this system, termed the GEM (Gel Encapsulated Microenvironment) assay were published today in the journal Microscopy. [Article]

April 21, 2016

Crystal Bioscience publishes the first demonstration of editing of the avian germline using CRISPR/Cas9 technology. [Article]

March 31, 2016

Cre recombinase was used to create a deletion of approximately 20kb in the genome of chickens. To date, this is the largest deletion engineered into the chicken genome and the first application of Cre technology in an avian species. The data were published in Transgenic Research. [Article]

March 20, 2016

Gordon Conference on Antibody Biology and Engineering in Galveston, TX. Bill Harriman presented a poster entitled “Human Antibodies from Chickens” that highlighted the first panel of fully human antibodies against a specific target generated from Crystal’s HuMab chickens.

February 25, 2016

Crystal Bioscience Develops First Non-Mammalian, Fully-Human Monoclonal Antibody Platform - Reaching a New Universe of Novel Epitopes. Crystal Biosciences announces the establishment of their novel antibody discovery platform.

January 18, 2015

PepTalk San Diego

• Yasmina Abdiche, Research Fellow Rinat-Pfizer, presented data on the binding kinetics and epitope coverage of antibodies retrieved through the Crystal platform in comparison to those isolated from more traditional sources.

• Yelena Bisharyan, Tetragenetics and Bill Harriman, CB, discussed antibodies obtained against ion channels that were retrieved in a joint program that combined Tetragenetics recombinant human ion channels with Crystal’s GEM screening.

• A poster describing antibodies against the ion channel Kv1.3 was presented by Ellen Collarini, Director of Cell Biology

October 14, 2015

CHI hosted a webinar entitled “How and Why to Use Chickens for Your Next Antibody Discovery Campaign” that included presentations by Yasmina Abdiche (Rinat/Pfizer), Jennifer Koenitzer (Boehringer Ingelheim) and Bill Harriman (Crystal Bioscience). The focus was quantifiable differences in epitope coverage and other performance measures between antibodies isolated from immunized chickens and antibodies from more traditional sources such as murine hybridoma or phage display. For more information see the following link:

[Click Here to Download the Webinar]

September 24, 2015

Discovery on Target, Boston, MA. Dr. Bill Harriman, CSO at Crystal Bioscience described the unique features of chicken antibodies to difficult targets that were recovered using the company’s proprietary GEM technology. Case studies demonstrating expanded epitope coverage and species cross-reactivity were provided for both wild-type and engineered birds.

June 2, 2015

Crystal Bioscience and Oxford Biotherapeutics announce a collaboration to produce panels of antibodies against undisclosed medically relevant antigens. The ability of chicken derived monoclonals to recognize epitopes not normally recognized by mammalian antibodies will be used to create novel assets within Oxford’s therapeutic pipeline.

May 1, 2015

Crystal Bioscience and Achaogen announce a collaboration to produce panels of antibodies against undisclosed targets. By combining Crystal’s “Smart-throughput” screen with the extended repertoire of immunized chickens, the collaboration seeks to isolate unique antibodies against novel bacterial antigens.

April 1, 2015

Crystal Bioscience and Tetragenetics announce a collaboration to produce a panel of antibodies directed towards ion channels. The program combines Tetragenetics’ unique antigen production capabilities with Crystal Bioscience’s chicken immunization platform and single B-cell screening.

March 20, 2015

The attributes of human antibodies expressed in vitro by chicken B cells in vitro was published in Frontiers in Immunology. The article entitled “A diverse repertoire of human immunoglobulin variable genes in a chicken B cell line is generated by both gene conversion and somatic hypermutation” is available at

February 3, 2015

The Consulate General of Canada in San Francisco and Silicon Valley hosted a roundtable panel of entrepreneurs including Rob Etches, CEO of Crystal Bioscience, to share insights with a select group of Canadian companies wishing to increase their visibility and footprint in the San Francisco Bay area.

November 20, 2014

World Health Organization consultation on scientific and regulatory pathways for the development, approval and use of monoclonal antibodies against infectious diseases…. Washington DC. Dr. Rob Etches described Crystal’s monoclonal discovery platforms in a presentation entitled “Avian antibody discovery platforms deliver next generation monoclonal antibodies”.

November 4, 2014

PEGS Europe, Lisbon. In a session that focused on tackling complex membrane targets, Dr. Bill Harriman discussed recent data illustrating various immunization strategies, and approaches to optimize single B cell cloning for recovery of bioactive antibodies.

October 21, 2014

The US Patent and Trademark Office has issued patent 8865,462 entitled “Sustained culture of avian gonocytes”. This patent covers one of the supporting technologies used at Crystal Bioscience to generate chickens producing fully human antibodies in response to immunization.

October 20, 2014

Oxford Journals published an article entitled written by the team at Crystal Bioscience describing the process of creating transgenic chickens using primordial germ cells and/or Crystal’s proprietary gonocytes. The article takes the reader through the steps of derivation of cell lines, design of transgene, introduction of DNA into cells, isolation of genetically modified cell lines, creation and evaluation of chimeric birds and establishment of strains of chickens bearing the desired genotype. This open access article can be viewed at

October 10, 2014

Discovery on Target, Boston, MA. Dr. Bill Harriman, CSO at Crystal Bioscience described application of the company’s proprietary antibody screening technology (the GEM platform) to the discovery of rare antibody specificities to difficult targets using high content screening of avian repertoires. Using examples from previous campaigns, Dr. Harriman showed efficient recovery of antibodies with desired biological activity and multi-species cross reactivity.

August 7, 2014

Elsevier is pleased to announce publication of Encyclopedia of Agriculture and Food Systems, in print and electronic form. The encyclopedia contains an article on Stem Cells authored by Dr. Rob Etches, President and CEO of Crystal Bioscience. The article can be accessed at

July 17, 2014

Dr. Rob Etches was the keynote speaker at the XIII Avian Immunology Research Group Workshop held at the University of Guelph, Canada. The tile of his presentation was “Inserting Random And Site-specific Changes Into The Genome Of Chickens”.

July 15, 2014

Dr. Rob Etches was a guest speaker at the PSA Symposium entitled “Avian Reproduction: Foundational Advances and Applied Applications” held in Corpus Christi,Texas. His presentation highlighted recent advances in genome engineering including inactivation of genes by homologous recombination and insertions into pre-determined locations within the genome. The IgH and IgL knock-outs and insertions of arrays of pseudogenes derived from human immunoglobulin genes were presented as examples of the technology.

March 24-28, 2014

Dr. Bill Harriman , CSO at Crystal Bioscience presented at the Gordon Conference on Antibody Biology and Engineering in Lucca, Italy. Dr. Harriman described the arrays of human antibody genes that have been incorporated into Crystal’s SynV chicken platform, and the enormous diversity they create in Crystal’s antibody panels.

January 14, 2014

Dr, Rob Etches, President and CEO of Crystal Bioscience presented to pharmaceutical and biotech management at the Biotech Showcase in San Francisco. His presentation highlighted the benefits of Crystal’s avian-discovery system for human monoclonals, over traditional humanized mice and rats, any hybridoma-based technology, and phage systems.

January 9, 2014

Crystal Bioscience is featured in Discovery & Development. Direct, Boehringer Ingelheim's January 2014 online newsletter; see it here.

January 7, 2014

Crystal Bioscience and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its GEM technology and chicken immunization platforms to discover antibodies to multiple targets selected by BI with the goal of discovering different development candidates that may result in new or better therapies. For more information see

January 2, 2014

Crystal Bioscience is pleased to announce the appointment of T. Todd Morrill as Senior Vice President of Business Development. Todd brings a wealth of experience to the company from his previous positions at Bio-Rad Laboratories where he was Head of Business Development and Corporate Development, at Trellis Biosciences where he was Chief Business Officer, and as a founder and Managing Director of Venture Merchant Group and Burrill & Company.

Todd’s responsibilities include strategy and business model design, and he is leading Crystal’s efforts to partner the company’s humanized monoclonal antibody platform, the GEM technology, and the SynV fully human antibody chicken.

December 11, 2013

Crystal Bioscience and collaborator Integral Molecular announce their successful campaign to generate antagonistic antibodies to the P2X3 ion channel. This is the first ion channel target to which chicken monoclonal antibodies have been raised. For more details see

December 11, 2013

Crystal Bioscience and collaborators from the United Arab Emirates today published a manuscript in Biology of Reproduction entitled “Characteristics of long-term cultures of avian primordial germ cells and gonocytes” (see PGC and gonocyte cultures are the underlying technology that make it possible to insert the genetic modifications required to create SynV chickens that, in combination with Crystal’s GEM technology, allow production of fully human monoclonal antibodies from an avian platform.

December 9, 2013

Dr. Phil Leighton, Director of Molecular Biology and Dr. Bill Harriman CSO at Crystal Bioscience attended the IBC 24th Annual Meeting on Antibody Engineering & Therapeutics held at the Hyatt Regency in Huntington Beach CA and presented a poster entitled “Immunoglobulin Knockout Chickens and Immunoglobulin Knock-in Chickens”. To view the poster, please click here.

November 26, 2013

The US Patent and Trademark Office has issued patent 8,592,644 entitled “Transgenic Animal for Production of Antibodies Having Minimal CDRs”. This patent covers one of Crystal’s strategies for generating the SynV chicken.

November 26, 2013

The first publication describing a targeted genetic modification in birds was published today by the team at Crystal Bioscience in an article entitled “Immunoglobulin knockout chickens via efficient homologous recombination in primordial germ cells”. To read the full PNAS paper, go to:

November 22, 2013

The team at Crystal Bioscience published the design of their transgenes encoding human V regions in their proprietary SynV chicken in an article entitled “Harnessing gene conversion in chicken B cells to create a human antibody sequence repertoire”. For more information, please see the “Technology” section of the website and the published article at

October 26, 2013

Dr. Marie-Cecile van De Lavoir, COO at Crystal Bioscience presented a paper at the International Forum on Avian Germplasm at Seoul National University, Korea entitled “Derivation efficiency of germline competent germ cell lines.”

September 26, 2013

Dr. Bill Harriman, CSO at Crystal Bioscience presented a paper entitled “Chicken monoclonal antibodies to native conformation GPCRs and ion channels” at the 11th Annual Discovery on Target conference in Boston MA.

August 13, 2013

Dr. Benni Schusser described derivation of monoclonal antibodies from transgenic chickens at the IX Transgenic Animal Conference in Lake Tahoe, CA.

April 9, 2013

The US Patent and Trademark Office has issued patent 8,415,173 entitled “Gel Microdrop Compostion and Method of Using Same”. This patent covers Crystal’s proprietary technology for the isolation and recovery of antigen specific antibodies from immunized chickens.

March 22, 2013

The GEM and SynV technologies were the focus of a presentation by Rob Etches, Co-founder, President and CEO of Crystal Bioscience at the workshop on Domestic Large Animals as Models for Agricultural and Biomedical Research sponsored by the University of Maryland, NIH and the USDA.

March 21, 2013

Crystal Bioscience is featured in the April 2013 issue of Biopharma Dealmakers. [read feature]

February 26, 2013

Dr. Benni Schusser from Crystal Bioscience and the University of Munich presented a poster entitled "Harnessing gene conversion in chicken B cells to create a human antibody repertoire" at the 11th B Cell Forum of the German Society of Immunology held in Schluchsee from Feb 25-17, 2013.

December 4, 2012

Dr. Bill Harriman from Crystal Bioscience and Dr. Roland Buelow from OMT presented the Omni-mAb platform at the IBC Life Sciences Antibody Engineering meeting in San Diego.

December 3, 2012

Crystal Bioscience has licensed its GEM technology to OMT for isolation of monoclonal antibodies from its proprietary Omni-Rats and Omni-Mice. [read more]

November 15, 2012

Integral Molecular and Crystal Bioscience Announce Research Collaboration to Develop Novel GPCR and Ion Channel Antibodies

PHILADELPHIA & EMERYVILLE, Calif.-- Crystal Bioscience and Integral Molecular have launched a research collaboration to generate panels of chicken monoclonal antibodies against undisclosed therapeutic GPCR and ion channel targets. The collaboration will leverage the synergy between Integral Molecular's Lipoparticle technology for immunization with native conformation multispanning membrane proteins and Crystal's GEM technology for the recovery of monoclonal antibodies against otherwise conserved proteins raised in immunized chickens...full article.

October 2012

Dr. Michael Ratcliffe, an internationally recognized expert in the field of avian immunology was appointed to the company’s advisory board. Dr. Ratcliffe has published extensively on avian B cell ontogeny and on the mechanisms contributing to the diverse repertoire of antibodies produced by the avian immune system. Dr. Ratcliffe is the Vice-Provost and Dean of Arts at Trinity College, Professor, Department of Immunology, University of Toronto and Senior scientist, Molecular and Cellular Biology, Sunnybrook Research Institute.

August 30, 2012

Dr. Benni Schusser, a post-doctoral fellow at Crystal Bioscience, presented an update on the SynV chicken to the 12th Avian Immunology Research Group at the Roslin Institute, Scotland. Dr. Schusser described the IgL and IgH knock outs, and the arrays of human light and heavy chain Vs that will be inserted into the IgL and IgH loci, respectively in the completed SynV chicken.

May 24, 2012

Crystal Bioscience publishes the first demonstration of robust interspecific germline transmission of primordial germ cells propagated in vitro. The full length article can be viewed These data demonstrate the potential for propagation of endangered species of birds using xenogeneic hosts.

May 15, 2012

Crystal Bioscience has been awarded a Phase II SBIR to support development of its proprietary SynV platform. In combination with Crystal’s proprietary GEM technology, the SynV platform provides access to fully human monoclonal antibodies against previously non-accessible targets.

April 1, 2012

Crystal Bioscience is awarded a Phase I SBIR grant from NIAID entitled “Novel therapeutic antibodies for the treatment and prevention of AIDS”.

back to top